Monte Carlo Expectation-Maximization algorithm to detect imprinting and maternal effects for discordant sib-pair data

Ruwani Herath ^a and Alex Trindade^b and Fangyuan Zhang^c

^{a,b,c}Department of Mathematics and Statistics, Texas Tech University, Lubbock, TX 79409-1042, USA

ARTICLE HISTORY

Compiled January 2, 2024

ABSTRACT

Numerous statistical methods have been developed to explore genomic imprinting and maternal effects, which are causes of parent-of-origin patterns in complex human diseases. Most of the methods, however, either only model one of these two confounded epigenetic effects, or make strong yet unrealistic assumptions about the population to avoid over- parameterization. A recent partial likelihood method $(LIME_{DSP})$ can identify both epigenetic effects based on discordant sibpair family data without those assumptions. Theoretical and empirical studies have shown its validity and robustness. As $LIME_{DSP}$ method obtains parameter estimation by maximizing partial likelihood, it is interesting to compare its efficiency with full likelihood maximizer. To overcome the difficulty in over-parameterization when using full likelihood, this study proposes a discordant sib-pair design based Monte Carlo Expectation Maximization $(MCEM_{DSP})$ method to detect imprinting and maternal effects jointly. Those unknown mating type probabilities, the nuisance parameters, are considered as latent variables in EM algorithm. Monte Carlo samples are used to numerically approximate the expectation function that cannot be solved algebraically. Our simulation results show that though this $MCEM_{DSP}$ algorithm takes longer computation time, it can generally detect both epigenetic effects with higher power, which demonstrates that it can be a good complement of $LIME_{DSP}$ method.

KEYWORDS

missing heritability; imprinting effect; maternal effect; discordant sib-pair design; Monte Carlo Expectation Maximization algorithm

1. Introduction

A genome-wide association study (GWAS) is an observational study of a genome-wide set of genetic variants in different individuals to see if any variant is associated with a trait. When applied to human data, GWAS compares participants' DNA with varying phenotypes for a particular trait or disease. GWAS is a powerful tool for identifying hundreds of genetic variants associated with complex human diseases and traits and has provided valuable insights into their genetic architecture. However, most of the variants identified have explained only a small proportion of complex diseases or traits, leading many to question "missing heritability"[1], which refers to the fact that single genetic variations cannot account for much of the heritability of

Corresponding author: Fangyuan Zhang, email: fangyuan.zhang@ttu.edu

diseases, behaviors, and other phenotypes. Other mechanisms may be also involved in this process, such as epigenetic modifications and transcriptional/ translational regulation[3][4]. In biology, epigenetics studies the heritable phenotype changes that do not involve alterations in the DNA sequence[5]. Thus, the epigenetic factors, including imprinting and maternal genotype effects, have become a research focus to detect missing heritability [6].

Genomic imprinting is an effect of an epigenetic process involving methylation and histone modifications that can silence the expression of a gene inherited from a particular parent without altering the genetic sequence. In diploid organisms, the somatic cells possess two copies of the genome, one inherited from the father and one from the mother. Each autosomal gene is therefore represented by two copies of alleles, with one copy inherited from each parent at fertilization. In mammals, however, a small proportion (<1%) of genes are imprinted, which means gene expression occurs from only one allele partially or completely [7]. The expressed allele is dependent upon its parental origin, i.e., unequal expression of a heterozygous genotype depending on whether the imprinted variant is inherited from the mother (maternal imprinting) or from the father (paternal imprinting). The imprinting effect is considered as a critical factor in understanding the interplay between the epigenome and genome [8]. For many diploid genes, even if the copy inherited from one parent is defective, there is a substitute allele from the other parent. However, in the case of imprinting, even though there are two copies of the gene, it behaves as a haploid (having a single set of unpaired chromosomes) for this gene because only one copy is expressed. In other words, no substitute allele makes imprinted genes more vulnerable to the adverse effects of mutations. Additionally, genes and mutations that might be generally recessive can be expressed if a gene is imprinted and the dominant allele is silenced [9]. Therefore, the disease can occur due to deletions or mutations in imprinting genes. [10]. Most common conditions involving imprinting include Beckwith-Wiedemann syndrome, Silver-Russell syndrome, pseudohypoparathyroidism [11], and transient neonatal diabetes mellitus can also involve imprinting [12].

Maternal effect is the situation where the phenotype of an organism is determined not only by the environment it experiences and its genotype, but also by the environment and genotype of its mother. In genetics, the maternal effects occur when the genotype of its mother determines the phenotype of an organism, irrespective of its own genotype [13]. This effect often occurs because the mother supplies mRNA or proteins during pregnancy. Maternal effect can be considered as a significant reason for varieties of diseases such as those that are related to pregnancy outcomes, childhood cancers and congenital disabilities [14], certain psychiatric illnesses [15], and some pregnancy complications [16].

Parent-of-origin effects occur when the phenotypic effect of an allele depends on whether it is inherited from an individual's mother or father [17]. Since both imprinting and maternal effects have parent-of-origin patterns [18] [19], they can be confounded with each other. For example, paternal imprinting can mimic maternal effect. Therefore, to identify imprinting and maternal effect, family-based data are needed to find the inheritance path, and it is better to detect the two epigenetic effects jointly.

1.1. Existing methods for detecting Imprinting and Maternal effects

Both parametric and non-parametric methods are suggested to study the imprinting and maternal effects. A Parental-Asymmetry Test (PAT) with case-parents trio data was proposed to detect the imprinting effect in nuclear families in the absence of maternal effect[20][21]. It was extended to accommodate general pedigree data by proposing Pedigree Parental-Asymmetry Test (PPAT), which uses all informative family trios. In addition, to accommodate pedigree data with missing genotypes, a Monte Carlo sampling based PPAT (MCPPAT) method was further developed[22]. The non-parametric methods are mainly used for detecting imprinting effect while assuming there are no maternal effect[23]. Though these non-parametric methods may be more powerful if there is indeed no maternal effect, under the existence of maternal effects, these methods suffer from potential confounding between imprinting and maternal effects, that can inflate false positive or false negative rates[24].

Numerous parametric methods can identify imprinting and maternal effects jointly based on full likelihood [25]. Case-parent triads and case-mother pairs are two popular study designs [26]. Almost all these methods, however, depend on strong yet unrealistic assumptions concerning mating type probabilities (nuisance parameters) to avoid over-parameterization, with the Logarithm Likelihood Ratio test (LL-LRT) as a classic example [27]. A partial Likelihood method for detecting Imprinting and Maternal effects (LIME) was then proposed as an exception. LIME can avoid overparameterization by deriving a partial likelihood that is free of the nuisance parameters through matching the case families with control families of the same familial genotypes [26] [28]. LIME is powerful and robust, but it requires the recruitment of separate control families which can be hard to obtain. Therefore, a LIME method based on a Discordant Sib-Pair design $LIME_{DSP}$ was proposed to receive the benefit of LIME without the requirement of separate control families. Discordant Sibpair design refers to that a nuclear family is recruited if there are at least an affected sibling and an unaffected sibling [29]. Similarly as LIME method, $LIME_{DSP}$ derives partial likelihood by matching affected proband-parent triads with unaffected proband-parent triads and factoring out common terms involving mating type probabilities.

Theoretical and empirical studies have shown the validity and robustness of LIME and $LIME_{DSP}$. The two methods, however, might lack of efficiency in parameter estimation, as they estimate parameters by maximizing partial likelihood, rather than full likelihood. Therefore, it is interesting to compare the estimation efficiency of these partial likelihood methods with a full likelihood method. To avoid over-parameterization problem in full likelihood, a Monte Carlo EM algorithm was proposed earlier for case - control family data. The results showed that the MCEM algorithm can detect both epigenetic effects with higher power and smaller standard error compared with the LIME method [30]. In this study, we will propose a discordant sibpair design based MCEM algorithm ($MCEM_{DSP}$) to detect both epigenetic effects and compare its performance with $LIME_{DSP}$.

1.2. MCEM algorithm

When missing values or latent variables exist, the direct computation of the Maximum Likelihood Estimate (MLE) is not usually achievable. Instead, we use expectation maximization algorithm, which can deal with models that depend on unobservable latent variables. The EM algorithm considers the fact that the distribution of the complete data, which include both observed data and latent variables, can be simpler to deal with [31]. Each EM iteration consists of two steps as the Expectation (E) and the Maximization (M) steps. The E - step computes the expected log-likelihood density of the complete data, conditionally on the observed data and the current parameter value. The parameter is updated in the M - step by maximizing the conditional expectation. The Monte Carlo EM (MCEM) algorithm is a modification of the EM algorithm which is used when the E - step in EM algorithm is not available in closed form. In MCEM, Monte Carlo simulations are used to generate realizations of the conditional hidden data through Markov Chain Monte Carlo (MCMC) routines such as the Gibbs and Metropolis - Hasting sampler [32]. Then the expectation in the E - step is replaced by the empirical mean of the complete log-likelihood. This is the principle of MCEM algorithm proposed by Wei and Tanner (1990) [33]. In our study to detect imprinting effect and maternal effect, as we have nine unobservable mating type probabilities involved in the full likelihood, we will overcome the over-parameterization problem by using the nuisance parameters as latent variables in MCEM algorithm to get maximum likelihood estimation.

In this dissertation, we seek to propose Monte Carlo Expectation Maximization algorithm $(MCEM_{DSP})$ to detect imprinting and maternal effect for discordant sibpair data. First, we have applied $MCEM_{DSP}$ algorithm for discordant sibpair data we generated and compared the results with $LIME_{DSP}$, which is an existing method for detecting imprinting and maternal effects based on partial likelihood. A major difficulty of using $MCEM_{DSP}$ is the high computation time. Secondly, we propose importance sampling based $MCEM_{DSP}$ as solution for the higher computation time of $MCEM_{DSP}$. It can give the similar results as $MCEM_{DSP}$ in shorter time. Finally, we applied $MCEM_{DSP}$ method to Framingham Heart Study (FHS) data to illustrate the utility of $MCEM_{DSP}$.

Chapter 02 contains general introduction for EM and MCEM algorithm with a Gaussian mixture data as an application example. Then we demonstrate the over-parameterization problem in the full likelihood for detecting the epigenetic effects based on discordant sibpair data, which is the reason for the assumptions concerning mating type probabilities in most existing methods. Then we propose the $MCEM_{DSP}$ method to overcome the over-parameterization problem by using mating type probabilities as the latent variables. To increase the time efficiency, we further develop an importance sampling based $MCEM_{DSP}$ method.

Chapter 03 contains extensive simulations of discordant family data with and without additional siblings for eight disease models and eight scenarios. We apply $MCEM_{DSP}$ and $LIME_{DSP}$ to the simulated data, and compare the type I error, power, and relative bias for parameter estimation. In addition, we also use the simulation data to demonstrate the time efficiency for importance sampling based $MCEM_{DSP}$.

Chapter 04 contains real data analysis. We apply $LIME_{DSP}$ and $MCEM_{DSP}$ to Framingham Heart Study data to identify SNPs with association, imprinting or maternal effects related to hypertension.

2. MCEM algorithm

2.1. Expectation Maximization algorithm

In this section, we summarize the expectation maximization algorithm which is known as the EM algorithm. This is a method to get likelihood maximizer when there are missing data or latent variables.

Let Y be the random vector corresponding to the observed data y with p.d.f. postulated as $g(y, \psi)$, where $\psi = (\psi_1, ..., \psi_d)^d$ is a vector of unknown parameter with parameter space Ω . In the context of EM algorithm, we consider the observed data y as incomplete and the complete data may contain some variables that are never observable. We define x as complete data and we let z denote the vector containing the additional data, referred to as the latent variables or missing data. Consider the EM algorithm as follows:

(1) Let $g_c(x, \psi)$ denote the p.d.f. of the random vector X corresponding to the complete data vector X = (Y, Z), where Y is the observed data, and Z is missing data or latent variable. Then we have the following complete-data log likelihood function as:

$$logL_c(\psi) = g_c(x,\psi) \tag{1}$$

(2) **E-Step:** Let $\psi^{(k)}$ be values for ψ at the iteration k. Then, the E-step requires the calculation of:

$$Q(\boldsymbol{\psi}, \boldsymbol{\psi}^{(k)}) = E_{\boldsymbol{\psi}^{(k)}}[log L_c(\boldsymbol{\psi})|Y]$$
(2)

Above equation simply says that at iteration k, we need to calculate the expectation of complete likelihood given the information we have for the observable data y and values $\psi^{(k)}$ for the unknown parameter ψ .

(3) **M-Step:** In M-step, we calculate the maximization of $Q(\psi, \psi^{(k)})$ with respect to ψ over the parameter space Ω and denote it as $\psi^{(k+1)}$. It can be shown that,

$$Q(\boldsymbol{\psi}, \boldsymbol{\psi}^{(k+1)}) \ge Q(\boldsymbol{\psi}, \boldsymbol{\psi}^{(k)})$$
(3)

and

$$L(\boldsymbol{\psi}^{(k+1)}, Y) \ge L(\boldsymbol{\psi}^{(k)}, Y) \tag{4}$$

for all $\boldsymbol{\psi} \in \Omega$.

We continue with the E-step and M-step until the difference $\psi^{(k+1)} - \psi^{(k)}$ changes by an arbitrary small amount.

In practice, a EM sequence will converge to a compact connected set of local maxima of the likelihood function; this limit set may or may not consist of a single point [34].

2.2. Monte Carlo Expectation Maximization algorithm

As in the previous section, in E-step of EM algorithm we need to take the expectation with respect to the conditional distribution of the missing data Z given the observed data Y = y. In many cases, however, evaluating the expectation in E-step of the EM algorithm does not yield closed form of the solutions. To overcome this problem, we can simulate random draws from target conditional distribution Z and approximate Q - function by Monte Carlo integration. To proceed this, let z_1, \ldots, z_m be random samples from $f(z|y, \psi^{(k)})$. Then we can use a Monte Carlo approximation to the expectation of EM algorithm as follow:

$$Q_{MC}(\psi|\psi^{(k)};y) = \frac{1}{m} \sum_{t=1}^{m} \log L_c(\psi|Y, Z^{(t)})$$
(5)

The update $\psi^{(k+1)}$ is the value of ψ that maximizes $Q_{MC}(\psi|\psi^{(k)};y)$.

2.3. Convergence of MCEM algorithm

The expectation-maximization algorithm is an algorithm for maximizing likelihood functions, specially when there are missing data or latent variables exist. If EM algorithm converges, it converges to a stationary point of the likelihood function. Even when the EM algorithm converges, there is no guarantee in general that it converges to a global maximum. However, the limit of an EM sequence can be a local maximum [35] or a saddle point [36]. Further, the convergence rate of the EM algorithm cannot be super linear [37]. When EM works well, the output of the MCEM algorithm is a sequence of parameter values that converges to the maximum likelihood estimate (MLE) [38]. For a given suitable initial value, a sequence of parameter values generated by the Monte Carlo Expectation Maximization algorithm will get arbitrarily close to a maximizer of the observed likelihood with a high probability [39].

2.4. Metropolis-Hastings Algorithm

The Monte Carlo EM algorithm is a stochastic version of the EM algorithm using MCMC methods to approximate the conditional distribution of the hidden data. A general method for generating samples from posterior distribution is Metropolis-Hastings algorithm.

Algorithm:

- (1) Sample a candidate value Z^* from a proposal distribution $g(.|z^{(t)})$
- (2) Compute Metropolis-Hastings ratio $R(z^{(t)}, Z^*)$

$$R(u,v) = \frac{f(v)g(u|v)}{f(u)g(v|u)},\tag{6}$$

where f(.) is the probability density function of the stationary distribution. (3) Sample a value for $Z^{(t+1)}$ according to the following:

$$Z^{(t+1)} = \begin{cases} Z^* & \text{with probability } \min[R(Z^{(t)}, Z)] \\ Z^{(t)} & \text{otherwise} \end{cases}$$
(7)

(4) Increment t and return to step 1 until it reaches to the stopping rule.

2.5. Importance Sampling Method

We'll consider the situation where the sample of the latent variables $Z_1, ..., Z_m$ in the E-step is obtained from a MCMC routine such as Gibbs sampler or Metropolis-Hasting algorithm with stationary distribution $g(Z|Y, \psi)$. Drawing an MCMC sample in each iteration of the MCEM algorithm could be very time consuming. We can use importance sampling to improve the computational expenses of the MCEM algorithm [32].

We initialize the algorithm with a sample $Z_1, Z_2, ..., Z_m$ from the distribution $g(Z|Y, \psi^{(0)})$, where $\psi^{(0)}$ is the initial value of the parameter ψ at the start of EM algorithm.

Then, at each iteration r, rather than obtaining a new sample from $g(Z|Y, \hat{\psi}^{(r)})$, with the most recent iterate, we can importance weight the original sample through the updated distribution $g(u|y, \psi^{(r)})$ That is,

$$Q_m(\psi|\hat{\psi}^{(r)}) = \frac{\sum_{t=1}^m w_t \ln f(Y, Z_t|\psi)}{\sum_{t=1}^m w_t}$$
(8)

where

$$w_t = \frac{g(Z_t|Y, \hat{\psi}^{(r)})}{g(Z_t|Y, \hat{\psi}^{(0)})}$$
(9)

In addition, we can show that

$$w_t = \frac{L(\hat{\psi}^{(r)}|Z_t, Y) / L(\hat{\psi}^{(r)}|Y)}{L(\hat{\psi}^{(0)}|Z_t, Y) / L(\hat{\psi}^{(0)}|Y)}$$
(10)

The likelihood $L(\psi|y)$ can be canceled in formula (2.4.3) and,

$$Q_m(\psi|\hat{\psi}^{(r)}) = \frac{\sum_{t=1}^m w_t' \ln f(Y, Z_t|\psi)}{\sum_{t=1}^m w_t'}$$
(11)

where,

$$w_t' = \frac{L(\hat{\psi}^{(r)}|Z_t, Y)}{L(\hat{\psi}^{(0)}|Z_t, Y)}$$
(12)

This choice will not affect the EM algorithm because the unknown normalizing constant

$$\frac{L(\hat{\boldsymbol{\psi}}^{(0)}|Y)}{L(\hat{\boldsymbol{\psi}}^{(r)}|Y)}$$

does not depend on the unknown value of ψ , and it does not come into play in the maximization step.

Algorithm:

- (1) Initialize $\psi^{(0)}$.
- (2) Generate $Z_1, ..., Z_m \sim g(Z|Y, \psi^{(o)})$ via an MCMC algorithm.
- (3) At iteration r + 1 compute the importance weights

$$w_t^{(r)} = \frac{L(\hat{\psi}^{(r)} | Z_t, Y)}{L(\hat{\psi}^{(0)} | Z_t, Y)}$$

(4) *E* - *step*: Estimate $Q(\boldsymbol{\psi}|\hat{\boldsymbol{\psi}}^{(r)})$ by

$$Q_m(\psi|\hat{\psi}^{(r)}) = \frac{\sum_{t=1}^m w_t^{(r)} \ln f(Z_t, Y|\psi)}{\sum_{t=1}^m w_t^{(r)}}$$

- (5) *M* step: Maximize $Q_m(\boldsymbol{\psi}|\hat{\boldsymbol{\psi}}^{(r)})$ to obtain $\hat{\boldsymbol{\psi}}^{(r+1)}$
- (6) Repeat Steps 3 through 5 until convergence.

There can be some drawbacks for importance sampling estimators. If the importance density $g(Z_t|Y, \hat{\psi}^{(r)})$ is not close enough to $g(Z_t|Y, \hat{\psi}^{(0)})$, then the weights will vary widely giving many samples little weight and allowing for a few variates to be overinfluetial. Also, if the initial values $\psi^{(0)}$ are poor, the estimator $Q_m(\psi|\hat{\psi}^{(r)})$ will take a long time to converge. We can alleviate this problem by initiating burn-in whereby for the first few iterations and a new sample is obtained from $g(Z_t|Y, \hat{\psi}^{(r)})$ rather than importance weighting.

- (1) Initialize $\psi^{(0)}$, and run burn-in.
 - (a) Set importance weights $w_t = 1$ for all t = 1, ..., m. At iteration b,
 - (b) Generate $Z_1, ..., Z_m \sim g(Z|Y, \psi^{(b)})$ via an MCMC algorithm.
 - (c) Run E and M steps above with r = b.
 - (d) Repeat Steps 1(b) and 1(c) for B burn-in iterations.
 - (e) Reinitialize $\psi^{(0)} = \psi^{(B)}$.

3. Applying Expectation Maximization Algorithm to detecting imprinting and Maternal Effects based on discordant sibpair design

3.1. Notation and Genetic Model

Consider a candidate genetic marker with two alleles M_1 and M_2 , which may code for disease susceptibility or epigenetic effect. We define M and F as the number of variant allele M_1 carried by the mother and the father in a nuclear family. They can take values 0,1 or 2, corresponding to genotype M_2M_2 , M_1M_2 or M_1M_1 , respectively. Let C_i be the random variable denoting the number of M_1 alleles carried by the child i, i = 1, 2, ..., k. Specifically, C_1 and C_2 are designated for the affected and unaffected probands, respectively, through which the discordant sib-pair family is recruited, whereas $C_i, i = 3, 4, ..., k$ are for the additional siblings. The indicator variable $D_i, i = 1, 2, ..., k$ denotes the disease status of children where 1 denotes being affected and 0 denotes being normal. Thus, for the affected child and unaffected child $D_1 = 1$ and $D_2 = 0$, respectively.

Assume the disease penetrance follows a multiplicative relative risk model

$$P(D=1|M=m, F=f, C=c) = \delta R_1^{I(c=1)} R_2^{I(c=2)} R_{im}^{I(c=1_m)} S_1^{I(m=1)} S_2^{I(m=2)}$$
(13)

where R_1 and R_2 denote the relative risk due to one or two copies of individual's own variant allele, R_{im} denotes relative risk due to imprinting effect, S_1 and S_2 denote the relative risk due to one or two copies of the mother's variant allele, and δ denote the disease phenocopy rate. The notation $c = 1_m$ indicates that the child's genotype is M_1M_2 and the variant allele is inherited from mother. We are interested in the model parameter estimation, collectively denoted as $\boldsymbol{\theta} = (\delta, R_1, R_2, R_{im}, S_1, S_2)$. Note that, all parameters are positive. Further, $R_{im} > 1, < 1$, and = 1 represent paternal, maternal, and no imprinting effect, respectively. Although there is no restriction placed on maternal effects, S_1 and S_2 , they are typically ≥ 1 , where the equality denotes no maternal effect.

3.2. The situation when $\mu_{ij}s$ are fixed unknown parameters

$$Y = \{n_{mfc_1c_2c_3...c_k}\}; k \ge 2$$

Denote μ_{mf} as the mating type probability of (M,F) = (m,f), that is, probability of parental pairs in which the mothers carry m copies and the fathers f of the variant allele. $n_{mfc_1c_2c_3...c_k}$ for k > 2 represent the number of families with certain familial genotype combinations.

Let $\boldsymbol{\mu} = (\mu_{00}, \mu_{01}, \mu_{02}, \mu_{10}, \mu_{11}, \mu_{12}, \mu_{20}, \mu_{21}, \mu_{22})$ denote the mating type probabilities which are fixed and unknown. We can define full likelihood as

$$P(Y; \boldsymbol{\theta}, \boldsymbol{\mu}) = \prod_{i=1}^{n} \left[P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, C_{3}^{(i)} = c_{3}, \dots, C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, \dots D_{k}^{(i)} | D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right]$$

$$= \prod_{i=1}^{n} \left[P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}) | D_{1}^{(i)} = 1, D_{2}^{(i)} = 0 \right)$$

$$.P(C_{3}^{(i)} = c_{3}, C_{4}^{(i)} = c_{4}, \dots, C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, D_{4}^{(i)}, \dots, D_{k}^{(i)} | M^{(i)} = m, F^{(i)} = f) \right]$$

$$= \prod_{i=1}^{n} \left[\left(\frac{P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right)$$

$$.P(C_{3}^{(i)} = c_{3}, C_{4}^{(i)} = c_{4}, \dots, C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, D_{4}^{(i)}, \dots, D_{k}^{(i)} | M^{(i)} = m, F^{(i)} = f) \right]$$

$$(14)$$

Here, we consider $k \ge 2$, since there should be at least one affected child and one unaffected child. The disease status for additional siblings can be arbitrary. When there are no additional siblings, the second term of the equation will equal to 1. The numerator of the first term on the right hand side of the equation can be expanded as

$$P(M^{(i)} = m, F^{(i)} = f, C_1^{(i)} = c_1, C_2^{(i)} = c_2, D_1^{(i)} = 1, D_2^{(i)} = 0)$$

$$= P(M = m, F = f).P(C_1 = c_1|M = m, F = f)$$

$$.P(C_2 = c_2|M = m, F = f).P(D_1 = 1|M = m, F = f, C_1 = c_1)$$

$$.P(D_2 = 0|M = m, F = f, C_2 = c_2)$$

$$= \mu_{mf}.P(C_1 = c_1|M = m, F = f).P(C_2 = c_2|M = m, F = f)$$

$$.P(D_1 = 1|M = m, F = f, C_1 = c_1).P(D_2 = 0|M = m, F = f, C_2 = c_2)$$
(15)

where

$$P(D_1 = 1|M = m, F = f, C_1 = c_1) = \delta R_1^{I(c_1=1)} R_2^{I(c_1=2)} R_{im}^{I(c_1=1_m)} S_1^{I(M=1)} S_2^{I(M=2)}$$
(16)

$$P(D_2 = 0|M = m, F = f, C_2 = c_2) = 1 - \delta R_1^{I(c_2=1)} R_2^{I(c_2=2)} R_{im}^{I(c_2=1_m)} S_1^{I(M=1)} S_2^{I(M=2)}$$
(17)

are obtained according to disease penetrance model.

In total, there are 29 possible combinations of genotypes for parents (M, F), affected child (C_1) and unaffected child (C_2) . Table 3.2 lists the corresponding joint probability of mother, father, affected child, unaffected child genotypes and proband disease status $P(M = m, F = f, C_1 = c_1, C_2 = c_2, D_1 = 1, D_2 = 0)$. (See Appendix 2) In the expressions in Table 3.2, the μ_{mf} 's (m = 0, 1, 2, f = 0, 1, 2) are the mating type probabilities, i.e., $\mu_{mf} = P(M = m, F = f)$. Note that, we do not make any assumptions about the mating symmetry, and therefore, μ_{mf} is not necessarily equal to μ_{fm} .

Type	m	f	c_1	c_2	$P(M = m, F = f, C_1 = c_1, C_2 = c_2, D_1 = 1, D_2 = 0)$
1	0	0	0	0	$\mu_{00}\delta(1-\delta)$
2	0	1	0	0	$\mu_{01}rac{1}{4}\delta(1-\delta)$
3	0	1	1	0	$\mu_{01}rac{1}{4}\delta r_1(1-\delta)$
4	0	1	0	1	$\mu_{01}\frac{1}{4}\delta(1-\delta r_1)$
5	0	1	1	1	$\mu_{01} \frac{1}{4} \delta r_1 (1 - \delta r_1)$
6	0	2	1	1	$\mu_{02}\delta r_1(1-\delta r_1)$
7	1	0	0	0	$\mu_{10}\frac{1}{4}\delta s_1(1-\delta s_1)$
8	1	0	1	0	$\mu_{10}\frac{1}{4}\delta r_1 s_1 r_{im} (1 - \delta s_1 r_{im})$
9	1	0	0	1	$\mu_{10}\frac{1}{4}\delta s_1 r_{im}(1-\delta r_1 s_1 r_{im})$
10	1	0	1	1	$\mu_{10}\frac{1}{4}\delta r_{1}s_{1}r_{im}(1-\delta r_{1}s_{1}r_{im})$
11	1	1	0	0	$\mu_{11} \frac{1}{16} \delta s_1 (1 - \delta s_1)$
12	1	1	1	0	$\mu_{11} \frac{1}{16} \delta r_1 s_1 (1 - \delta s_1) (1 + r_{im})$
13	1	1	0	1	$\mu_{11} \frac{1}{16} \delta s_1 [2 - \delta r_1 s_1 (1 + r_{im})]$
14	1	1	1	1	$\mu_{11\frac{1}{16}}\delta r_1 s_1 (1-\delta s_1)(1+r_{im})[2-\delta r_1 s_1 (1+r_{im})]$
15	1	1	2	0	$\mu_{11} \frac{1}{16} \delta r_2 s_1 (1 - \delta s_1)$
16	1	1	0	2	$\mu_{11,\frac{1}{16}}\delta s_1(1-\delta r_2 s_1)$
17	1	1	2	2	$\mu_{11} \frac{1}{16} \delta r_2 s_1 (1 - \delta r_2 s_1)$
18	1	1	1	2	$\mu_{11} \frac{1}{16} \delta r_1 s_1 (1 + r_{im}) (1 - \delta r_2 s_1)$
19	1	1	2	1	$\mu_{11} \frac{1}{16} \delta r_2 s_1 [2 - \delta r_1 s_1 (1 + r_{im})]$
20	1	2	1	1	$\mu_{12}\frac{1}{4}\delta r_1 s_1 (1 - \delta r_1 s_1)$
21	1	2	1	2	$\mu_{12}rac{1}{4}\delta r_1 s_1 (1-\delta r_2 s_1)$
22	1	2	2	1	$\mu_{12}\frac{1}{4}\delta r_2 s_1 (1 - \delta r_1 s_1)$
23	1	2	2	2	$\mu_{12}\frac{1}{4}\delta r_2 s_1 (1 - \delta r_2 s_1)$
24	2	0	1	1	$\mu_{12}\frac{1}{4}\delta r_2 s_1 (1 - \delta r_2 s_2)$
25	2	1	1	1	$\mu_{20}\delta r_1 s_2 r_{im}(1 - \delta r_1 s_2 r_{im})$
26	2	1	2	1	$\mu_{21\frac{1}{4}}\delta r_1 s_2 r_{im} (1 - \delta r_1 s_2 r_{im})$
27	2	1	1	2	$\mu_{21}\frac{1}{4}\delta r_2 s_2 (1 - \delta r_1 s_2 r_{im})$
28	2	1	2	2	$\mu_{21} \frac{1}{4} \delta r_2 s_2 (1 - \delta r_2 s_2)$
29	2	2	2	2	$\mu_{22}\delta r_2 s_2 (1-\delta r_2 s_2)$

Table 1.: Joint probability of mother - father - affected child - unaffected child genotype and proband disease status

The denominator of the first term of the right hand side of the equation and the second term can be expanded as follows.

$$P(D_1^{(i)} = 1, D_2^{(i)} = 0)$$

= $\sum_{m, f, c_1, c_2} P(M = m, F = f, C_1 = c_1, C_2 = c_2, D_1 = 1, D_2 = 0)$ (18)

and

$$P(C_3^{(i)} = c_3, C_4^{(i)} = c_4, ..., C_k^{(i)} = c_k, D_3^{(i)}, D_4^{(i)}, ..., D_k^{(i)} | M^{(i)} = m, F^{(i)} = f)$$

= $P(C_3 = c_3 | M = m, F = f)....P(C_k = c_k | M = m, F = f)$
. $P(D_3 | M = m, F = f, C_3 = c_3)...P(D_k | M = m, F = f, C_k = c_k)$ (19)

Therefore, we can see that the full likelihood includes both parameter vector $\boldsymbol{\theta}$ of

interest and nuisance parameter vector $\boldsymbol{\mu}$. It is hard to maximize the full likelihood function directly with the over-parameterization problem. This is the reason why many methods need to make assumptions concerning mating type probabilities, such as mating symmetry ,i.e., $\mu_{ij} = \mu_{ji}$, to reduce the number of parameters. To overcome this problem of over-parameterization without making those strong and unrealistic assumptions, we propose $MCEM_{DSP}$ algorithm to get the likelihood maximizer with the nuisance parameters used as latent variables.

3.3. Applying $MCEM_{DSP}$

Let the random vector X be complete data that consist of the random vectors Y and Z where

$$Z_{ij} = \mu_{ij} \ i = 0, 1, 2 \ j = 0, 1, 2$$
$$Y = \{n_{mfc_1c_2c_3...c_k}\}; k \ge 2$$

In this study, we consider the mating type probabilities are latent variables. We use the Expectation Maximization (EM) algorithm to compute maximum likelihood estimates in the problems with latent variables.

We can define $P(Y|Z = \mu) = P(Y; \mu)$ as equation 2.5.2, where the only difference is mating type probabilities are viewed as latent random variables, rather than fixed parameters.

We consider the mating type probabilities μ_{ij} 's, are random values that follow Dirichlet distribution $\pi(Z)$.

$$\pi(Z) = \frac{1}{B(\alpha)} \prod_{m=0}^{2} \prod_{f=0}^{2} \mu_{mf}^{\alpha_{mf}-1}$$
(20)

Here, $\boldsymbol{\alpha} = (\alpha_{00}, \alpha_{01}, \alpha_{02}, \alpha_{10}, \alpha_{11}, \alpha_{12}, \alpha_{20}, \alpha_{21}, \alpha_{22})$ is the concentration parameter. To apply EM algorithm, the complete log likelihood function can be defined as

$$logL_{c}(\psi) = log\{P(Y|Z)P(Z)\}$$

$$= log\left\{ \left[\prod_{i=1}^{n} \left(P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, C_{3}^{(i)} = c_{3}, \dots, C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, \dots D_{k}^{(i)} | D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right] . \pi(Z) \right\}$$

$$= \sum_{i=1}^{n} \left\{ log\left[\frac{P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right] + log\left(P(C_{3}^{(i)} = c_{3}, C_{4}^{(i)} = c_{4}, \dots, C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, D_{4}^{(i)} \right] + log\pi(Z)$$

$$(21)$$

We define ψ as

 $\boldsymbol{\psi} = (\boldsymbol{\theta}, \, \boldsymbol{\alpha})$

where $\boldsymbol{\theta} = (\delta, R_1, R_2, R_{im}, S_1, S_2)$ and $\boldsymbol{\alpha} = (\alpha_{00}, \alpha_{01}, \alpha_{02}, \alpha_{10}, \alpha_{11}, \alpha_{12}, \alpha_{20}, \alpha_{21}, \alpha_{22})$ The initial values for $\boldsymbol{\psi}^0 = (\boldsymbol{\theta}^0, \boldsymbol{\alpha}^0)$ are taken in the way that $\boldsymbol{\theta}^0$ is from the results for $LIME_{DSP}$ method and $\boldsymbol{\alpha}^0 = \left[\left(\frac{\boldsymbol{n}_{mf}}{\sum \boldsymbol{n}_{mf}} \right) \times \mathbf{100} \right] + \mathbf{1}.$

E-Step:

For E-step, we calculate $Q(\boldsymbol{\psi}; \boldsymbol{\psi}^k)$ as follows

$$Q(\psi; \psi^{k}) = E_{\psi^{k}} \{ logL_{c}(\psi) | Y \}$$

$$= E_{\psi^{k}} \left\{ \sum_{i=1}^{n} \left\{ log \left[\frac{P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right] \right\}$$

$$+ \log \left(P(C_{3}^{(i)} = c_{3}, C_{4}^{(i)} = c_{4}, ..., C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, D_{4}^{(i)}, ..., D_{k}^{(i)} | M^{(i)} = m, F^{(i)} = f) \right) \right\}$$

$$+ log \pi(Z) | Y \right)$$

$$(22)$$

where

$$\begin{split} E_{\psi^{k}} & \left(\sum_{i=1}^{n} \left\{ log \left[\frac{P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right. \right. \right. \\ & + \log \left(P(C_{3}^{(i)} = c_{3}, C_{4}^{(i)} = c_{4}, ..., C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, D_{4}^{(i)} \right. \\ & \left. , ..., D_{k}^{(i)} | M^{(i)} = m, F^{(i)} = f \right) \right) \right\} | Y \right) \\ & = \int \sum_{i=1}^{n} \left\{ log \left[\frac{P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right. \right. \\ & \left. + \log \left(P(C_{3}^{(i)} = c_{3}, C_{4}^{(i)} = c_{4}, ..., C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, D_{4}^{(i)} \right. \\ & \left. , ..., D_{k}^{(i)} | M^{(i)} = m, F^{(i)} = f \right) \right) \right\} . \\ f_{\psi^{k}}(Z|Y) . dZ \end{split}$$

and

$$E_{\psi^{k}}(log\pi(Z)|Y) = E_{\psi^{k}}\left(log\left\{\frac{1}{B(\alpha)}\prod_{m=0}^{2}\prod_{f=0}^{2}Z_{mf}^{\alpha_{mf}-1}\right\}|Y\right)$$

$$= E_{\psi^{k}}\left(-logB(\alpha) + (\alpha_{mf}-1)\sum_{m=0}^{2}\sum_{f=0}^{2}logZ_{mf}\right)$$

$$= \int \left(-logB(\alpha) + (\alpha_{mf}-1)\sum_{m=0}^{2}\sum_{f=0}^{2}logZ_{mf}\right) \cdot f_{\psi^{k}}(Z|Y) \cdot dZ$$
(24)

Since we cannot calculate the integrals in the above equations explicitly, we use Metropolis-Hastings algorithm to take samples from $f_{\psi^k}(Z|Y)$ and get the Monte Carlo estimation of $Q(\psi, \psi^{(k)})$. Here we use proposal distribution $g(Z) = \pi^{(\alpha^k)}(Z)$. The stationary distribution is

Here we use proposal distribution $g(Z) = \pi^{(\boldsymbol{\alpha}^k)}(Z)$. The stationary distribution is $f(Z) = P^{(\boldsymbol{\psi}^k)}(Z|y)$. Here,

$$\pi^{(\boldsymbol{\alpha}^k)}(Z) = \frac{1}{B(\boldsymbol{\alpha}^k)} \prod_{m=0}^2 \prod_{f=0}^2 Z_{mf}^{\boldsymbol{\alpha}^k_{mf}-1}$$
(25)

and we consider $\boldsymbol{\alpha}^k$ are obtained from the last EM iteration. In the first step we take a sample Z^* from $\pi^{(\alpha^k)}(Z)$ distribution. Then we take turns to update two elements of Z random vector at a time to improve the acceptance rate of EM algorithm. Suppose we want to update the first two element of the sample based on the conditional distribution of $Z_{A_1}|Z_{A_2}$ where $Z_{A_1} = (Z_1, Z_2)$ and $Z_{A_2} = (Z_3, ..., Z_9)$. Then we can show the conditional distribution is as follows

$$f_{Z_1, Z_2|Z_3, \dots, z_9}(z_1, z_2|z_3, \dots, z_9) = \frac{\Gamma(\sum_{i=1}^2 \alpha_i)}{\prod_{i=1}^2 \Gamma(\alpha_i)} \prod_{i=1}^2 \left[z_i \left(1 - \sum_{j=3}^k z_j \right)^{-1} \right]^{\alpha_i - 1} \left(1 - \sum_{j=3}^k z_j \right)^{-1}$$
(26)

Then, we can calculate Metropolis-Hastings ratio as follow:

$$R(Z^{(t)}, Z^*) = \frac{f(Z^*)\pi^{(\boldsymbol{\alpha}^k)}(Z^{(t)})}{f(Z^{(t)})\pi^{(\boldsymbol{\alpha}^{(k)})}(Z^*)} = \frac{P^{(\boldsymbol{\psi}^k)}(Z^*|Y)\pi^{(\boldsymbol{\alpha}^k)}(Z^{(t)})}{P^{(\boldsymbol{\psi}^k)}(Z^{(t)}|Y)\pi^{(\boldsymbol{\alpha}^k)}(Z^*)}$$

$$\propto \frac{P^{(\boldsymbol{\theta}^k)}(Y|Z^*)\pi^{(\boldsymbol{\alpha}^k)}(Z^*)\pi^{(\boldsymbol{\alpha}^k)}(Z^{(t)})}{P^{(\boldsymbol{\theta}^k)}(Y|Z^{(t)})\pi^{(\boldsymbol{\alpha}^k)}(Z^{(t)})\pi^{(\boldsymbol{\alpha}^k)}(Z^*)} = \frac{P^{(\boldsymbol{\theta}^k)}(Y|Z^*)}{P^{(\boldsymbol{\theta}^k)}(Y|Z^{(t)})}$$
(27)

where $\boldsymbol{\theta}^k$ represents the values for the parameters $\delta, R_1, R_2, R_{im}, S_1, S_2$ from previous EM iteration.

Finally, we can find sample Z^{t+1} as follows:

$$Z^{(t+1)} = \begin{cases} Z^* & \text{with probability } \min(R(Z^{(t)}, Z^*), 1) \\ Z^{(t)} & \text{otherwise} \end{cases}$$

In the k^{th} iteration of the MCEM algorithm, we use MH algorithm to generate 10000 sample points $Z_{kmf}^{(1)}, Z_{kmf}^{(2)}, ..., Z_{kmf}^{(10000)}$ from probability distribution $f_{\psi^{(k)}}(Z|Y)$ as shown above. We determine 10000 sample points are good enough for MH algorithm to converge, as Brooks Gelman scale reduction factor is very close to 1 for 10000 sample size in simulation [40]. Then we use Monte-Carlo method to estimate integration in E -step as follows

$$\begin{split} \dot{E}_{\psi^{(k)}} \{ log P_{\theta}(Y|Z) | Y \} \\ &= \frac{1}{10000} \sum_{t=1}^{n} \sum_{j=1}^{10000} \left[log \left(\frac{P(M^{(i)} = m, F^{(i)} = f, C_1^{(i)} = c_1, C_2^{(i)} = c_2, D_1^{(i)} = 1, D_2^{(i)} = 0) \right) \\ &+ log \left(P(C_3^{(i)} = c_3, C_4^{(i)} = c_4, ..., C_k^{(i)} = c_k, D_3^{(i)}, D_4^{(i)}, ..., D_k^{(i)} | M^{(i)} = m, F^{(i)} = f \right) \right)] \end{split}$$

$$(28)$$

where

~

$$P(M^{(i)} = m, F^{(i)} = f, C_1^{(i)} = c_1, C_2^{(i)} = c_2, D_1^{(i)} = 1, D_2^{(i)} = 0)$$

= $Z_{kmf}^{(j)} P(C_1 = c_1 | M = m, F = f) . P(C_2 = c_2 | M = m, F = f)$
. $P(D_1 = 1 | M = m, F = f, C_1 = c_1) . P(D_2 = 0 | M = m, F = f, C_2 = c_2)$
(29)

and

$$(C_3^{(i)} = c_3, C_4^{(i)} = c_4, ..., C_k^{(i)} = c_k, D_3^{(i)}, D_4^{(i)}, ..., D_k^{(i)} | M^{(i)} = m, F^{(i)} = f)$$

= $P(C_3 = c_3 | M^{(i)} = m, F^{(i)} = f) P(C_k = c_k | M^{(i)} = m, F^{(i)} = f)$
 $.P(D_3 | M^{(i)} = m, F^{(i)} = f, C_3 = c_3) ... P(D_k | M^{(i)} = m, F^{(i)} = f, C_k = c_k)$ (30)

$$E_{\psi^{(k)}}\{log P_{\alpha}(Z)|Y\} = \frac{1}{10000} \sum_{j=1}^{10000} \left[-log B(\alpha) + (\alpha_{m_i, f_i} - 1) \sum_{m=0}^{2} \sum_{f=0}^{2} log Z_{kmf}^{(j)} \right]$$
(31)

Then we can define $Q_{MC}(\boldsymbol{\psi};\boldsymbol{\psi}^{(k)})$ as follows

$$Q_{MC}(\boldsymbol{\psi}, \boldsymbol{\psi}^{(k)}) = \hat{E}_{\boldsymbol{\psi}^{(k)}} \{ log P_{\boldsymbol{\theta}} (Y|Z) | Y \} + E_{\boldsymbol{\psi}^{(k)}} \{ log P_{\boldsymbol{\alpha}} (Z) | Y \}$$
(32)

M Step:

For the maximization step, we maximize $Q_{MC}(\psi; \psi^{(k)})$ which is the sum of above two equations with respect to the parameters

 $\boldsymbol{\psi} = (\delta, R_1, R_2, R_{im}, S_1, S_1, \alpha_{00}, \alpha_{01}, \alpha_{02}, \alpha_{10}, \alpha_{11}, \alpha_{12}, \alpha_{20}, \alpha_{21}, \alpha_{22})$ Note that the first term of $Q_{MC}(\boldsymbol{\psi}; \boldsymbol{\psi}^{(k)})$ is only related to $\boldsymbol{\theta}$, and the second term of $Q_{MC}(\boldsymbol{\psi}; \boldsymbol{\psi}^{(k)})$ is only related to $\boldsymbol{\alpha}$. Therefore, to maximize $Q_{MC}(\boldsymbol{\psi}; \boldsymbol{\psi}^{(k)})$, we can separately maximize the first term with respect to $\boldsymbol{\theta}$, and maximize the second term with respect to $\boldsymbol{\alpha}$.

3.4. Applying Importance sampling based on MCEM_{DSP} algorithm

It is very time consuming to generate Z_{mf} from posterior distribution using $MCEM_{DSP}$, so we propose to use importance sampling method as the solution for it. Let k be the iteration number of EM algorithm.

Then up to 10^{th} iteration we generate Z_{mf} using the posterior distribution $f(Z|Y; \boldsymbol{\psi}^{(k)})$ as in the $MCEM_{DSP}$ method. At $k \geq 11$ iterations, we'll use the importance weights to calculate $Q_{MC}(\psi; \psi^k)$ as follows.

$$w_t^{(k)} = \frac{L(\hat{\psi}^{(k)}|Z_{10}^{(t)}, Y)}{L(\hat{\psi}^{(0)}|Z_{10}^{(t)}, Y)} = \frac{P(Y|Z_{10}^{(t)}; \boldsymbol{\theta}^k) \cdot P(Z_{10}^{(t)}; \boldsymbol{\alpha}^k)}{P(Y|Z_{10}^{(t)}; \boldsymbol{\theta}^{10}) \cdot P(Z_{10}^{(t)}; \boldsymbol{\alpha}^{10})} = \frac{P(Y|Z_{10}^{(t)}; \boldsymbol{\theta}^k) \cdot \pi^{\boldsymbol{\alpha}^k}(Z_{10})}{P(Y|Z_{10}^{(t)}; \boldsymbol{\theta}^{10}) \cdot \pi^{\boldsymbol{\alpha}^{10}}(Z_{10})}$$
(33)

Here, $P(Y|Z_{10}^{(t)}; \boldsymbol{\theta}^k)$ the probability density function of Y conditional on t^{th} monte carlo sample of Z at 10^{th} iteration with parameter $\boldsymbol{\theta} = \boldsymbol{\theta}^k$ the values from the last importance sampling based $MCEM_{DSP}$ iteration for the parameters $\delta, R_1, R_2, R_{im}, S_1, S_2$. Then we can compute the Q function in E step as

$$Q_{MCIm}(\psi; \psi^k) = \frac{\sum_{t=1}^m w_t^{(k)} \ln f(Z_t, Y | \psi)}{\sum_{t=1}^m w_t^{(k)}}$$
(34)

For maximization, since $\sum_{t=1}^{k} w_t^k$ does not depend on unknown parameters, we can simply maximize the numerator with respect to $\boldsymbol{\theta}$ and $\boldsymbol{\alpha}$ to update ψ .

$$\sum_{t=1}^{m} w_t^{(k)} \ln f(Z_t, Y|\psi) = \sum_{t=1}^{m} w_t^{(k)} \ln f(Y|Z_t; \theta) + \sum_{t=1}^{m} w_t^{(k)} \ln f(Z_t|\alpha)$$
(35)

The first term of the numerator of Q_{MCIm} is only related to θ and the second term of Q_{MCIm} is only related to α . So we can maximize Q_{MCIm} by separately maximizing the first part with respect to θ and maximizing the second part with respect to α .

3.5. Hypothesis Testing

To test whether the candidate marker has association effect, imprinting effect, and maternal effect with the disease. We need to consider the follower four models.

(1) Full model

In this model, we consider child's own genotype effect, imprinting effect, and maternal effect are all possibly related to the disease.

$$P(D=1|M=m, F=f, C=c) = \delta R_1^{I(c=1)} R_2^{I(c=2)} R_{im}^{I(c=1_m)} S_1^{I(m=1)} S_2^{I(m=2)} S_2^{I(m=2)}$$

(2) Null model

For null model, we consider there is no effect from child's own genotype effect, imprinting effect, or maternal effect in the model, i.e., the disease penetrance is the same as the phenocopy rate.

$$P(D = 1 | M = m, F = f, C = c) = \delta$$

(3) Non-Imprinting effect model In this model there is no imprinting effect, i.e., $R_{im} = 1$.

$$P(D=1|M=m,F=f,C=c) = \delta R_1^{I(c=1)} R_2^{I(c=2)} S_1^{I(m=1)} S_2^{I(m=2)} S_2^{I$$

(4) Non-Maternal effect model

In this model, there is no maternal effect, i.e., S_1 and S_2 are both equal to 1.

$$P(D=1|M=m,F=f,C=c) = \delta R_1^{I(c=1)} R_2^{I(c=2)} R_{im}^{I(c=1_m)}$$

Association effect

For testing association effect, we check the following hypothesis.

$$H_0: R_1 = R_2 = R_{im} = S_1 = S_2 = 1$$
 (NULL model)
vs.

 ${\cal H}_a$: at least one of these parameters is not equal to 1 (Full model)

The test statistic is,

$$T_1 = \frac{1}{10000} \sum_{t=1}^{10000} 2 \left[log P_{FULL} \left(Y | Z^{(t)} \right) - log P_{NULL} \left(Y | Z^{(t)} \right) \right]$$
(36)

Here, $P_{FULL}(Y|Z^{(t)})$ is the likelihood value for the full model and $P_{NULL}(Y|Z^{(t)})$ is the likelihood for NULL model.

When there are additional siblings, the test statistic asymptotically follows χ_5^2 , while when there are no additional siblings, the test statistic asymptotically follow χ_6^2 . This is because in log P(Y|Z) formula, the discordant sibpair part is free of all the parameters in $\boldsymbol{\theta}$ ($\delta(1-\delta)$) appear in both numerator and denominator and can be cancelled), while additional sibling part includes δ .

$$\begin{split} \log P(Y|Z) &= \sum_{i=1}^{n} \left\{ \log \left[\frac{P(M^{(i)} = m, F^{(i)} = f, C_{1}^{(i)} = c_{1}, C_{2}^{(i)} = c_{2}, D_{1}^{(i)} = 1, D_{2}^{(i)} = 0) \right] \right. \\ &+ \log \left(P(C_{3}^{(i)} = c_{3}, C_{4}^{(i)} = c_{4}, ..., C_{k}^{(i)} = c_{k}, D_{3}^{(i)}, D_{4}^{(i)}, ..., D_{k}^{(i)} | M^{(i)} = m, F^{(i)} = f) \right) \right\} \\ &= \sum_{i=1}^{n} \left\{ \log \left[\frac{\mu_{mf} \cdot P(C_{1} = c_{1} | M = m, F = f) \cdot P(C_{2} = c_{1} | M = m, F = f) \delta(1 - \delta)}{\sum_{m, f, c_{1}, c_{2}} \mu_{mf} \cdot P(C_{1} = c_{1} | M = m, F = f) \cdot P(C_{2} = c_{1} | M = m, F = f) \delta(1 - \delta)} \right] \right. \\ &+ \log \left(P(C_{3} = c_{3} | M = m, F = f) \dots P(C_{k} = c_{k} | M = m, F = f) \right. \\ &+ \log \left(P(C_{3} = c_{3} | M = m, F = f) \dots P(C_{k} = c_{k} | M = m, F = f) \right. \\ &\left. P(D_{3} | M = m, F = f, C_{3} = c_{3}) \dots P(D_{k} | M = m, F = f, C_{k} = c_{k} \right) \right\} \\ &= \sum_{i=1}^{n} \left\{ \log \left[\frac{\mu_{mf} \cdot P(C_{1} = c_{1} | M = m, F = f) \cdot P(C_{2} = c_{1} | M = m, F = f)}{\sum_{m, f, c_{1}, c_{2}} \mu_{mf} \cdot P(C_{1} = c_{1} | M = m, F = f) \cdot P(C_{2} = c_{1} | M = m, F = f)} \right] \\ &+ \log \left(P(C_{3} = c_{3} | M = m, F = f) \dots P(C_{k} = c_{k} | M = m, F = f) \right. \\ &\left. \delta \Sigma_{i=3}^{k} D_{i} (1 - \delta)^{k-2} - \Sigma_{i=3}^{k} D_{i} \right) \right\} \end{aligned}$$

Imprinting effect

To test the imprinting effect, we consider the following hypothesis.

$$H_0: R_{im} = 1 \text{ (Non-imprinting model)}$$
vs.
$$H_a: R_{im} \neq 1 \text{ (Full model)}$$

The test statistic is

$$T_2 = \frac{1}{10000} \sum_{t=1}^{10000} 2 \left[log P_{FULL} \left(Y | Z^{(t)} \right) - log P_{Non-Imprinting} \left(Y | Z^{(t)} \right) \right] \sim \chi_1^2 \qquad (38)$$

under null hypothesis.

Maternal effect

There exists maternal effect means $S_1 \neq 1$ or $S_2 \neq 1$. Thus, the hypothesis for the maternal effect is

$$H_0: S_1 = S_2 = 1$$
 (Non-Maternal effect model)
vs.
 $H_a: S_1 \text{ or } S_2 \text{ is not equal to } 1$ (Full model)

The test statistic for check the above hypothesis is,

$$T_3 = \frac{1}{10000} \sum_{t=1}^{10000} 2 \left[log P_{FULL} \left(Y | Z^{(t)} \right) - log P_{Non-Maternal} \left(Y | Z^{(t)} \right) \right] \sim \chi_2^2 \qquad (39)$$

under null hypothesis.

For all of above three cases, p-value is calculated based on the test statistic and then

compared with significance level.

4. Simulation

To examine the performance of $MCEM_{DSP}$ method, we consider eight disease models and eight scenarios.

In table 3.1, the first setting for the disease model corresponds to null model with no genetic effect. The settings 2 and 3 correspond to the disease models that there is neither imprinting nor maternal effect. Setting 4 only has maternal effect. Settings 5 and 6 only have imprinting effect. Settings 7 and 8 have both imprinting and maternal effects. Under each model, we investigate eight different scenarios in which there are three factor values: minor allele frequency (MAF) {0.1, 0.3}, disease prevalence P(D = 1) (PREV) {0.05(*rare*), 0.15(*common*)} and condition for Hardy-Weinberg equilibrium (HWE) {1 = Yes, 0 = No}. Note that, p is the frequency for the minor

								T (1	
	Dise	ease N	lodel		Factor values					
Parameters									Scenarios	3
Settings	R_1	R_2	R_{im}	S_1	S_2		Settings	MAF	PREV	HWE
1	1	1	1	1	1		1	0.1	0.05	0
2	2	3	1	1	1		2	0.3	0.05	0
3	1	3	1	1	1		3	0.1	0.15	0
4	1	3	1	2	2		4	0.3	0.15	0
5	1	3	3	1	1		5	0.1	0.05	1
6	3	3	1/3	1	1		6	0.3	0.05	1
7	1	3	3	2	2		7	0.1	0.15	1
8	3	3	1/3	2	2		8	0.3	0.15	1

Table 2.: Eight simulation settings of relative risks and eight scenarios with three factors

allele and (1-p) is wild allele frequency. As a result of population HWE, allelic exchangeability and mating symmetry will be implied. In cases that HWE is violated, we use a common assumption in population genetics and assume that a common cause of non-random matings is inbreeding. Then, in such cases, the probability of genotypes containing 0, 1, and 2 minor alleles are $(1-p)^2(1-\zeta) + (1-p)\zeta$, $2p(1-p)(1-\zeta)$ and $p^2(1-\zeta) + p\zeta$, respectively, where ζ is the inbreeding parameter. When HWE holds, $\zeta = 0$. ζ is set to be 0.1 and 0.3 for males and females, respectively, when HWE does not hold. Note that with the specification of each scenario and a disease model, the penetrance probability is fully specified.

We generate 500 replications under each of these 64 settings. To check the influence of sample size, each replicate consists of 100 or 500 discordant sibpair families. Firstly, parental genotypes are generated based on MAF and HWE. Then, the genotypes of their proband children are created according to the transmission probability assuming no recombination. Affection status D of the probands are determined by a Bernoulli trial, with the success probability calculated based on disease penetrance model. A family with an affected child and an unaffected child is recruited as a discordant sibpair family. The process of generating M, F,C, and D is repeated until we have collected sufficient numbers of discordant sibpair families to meet the preset sample size. We further simulate the genotype and disease status of a third child for each family as an additional sibling. We denote the data without additional sibling as "DS", and denote the data with one additional sibling in each family as "DS+1".

5. Results

5.1. Type I error and power

Under eight disease models and eight scenarios, we compare the type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ for data types "SD" and "SD+1". Each figure from Figures 3.1 and 3.2 represent first two scenarios for sample size 100 (Appendix figures 1 - 6 are for the other scenarios). In the figures, the three rows represent association effect, imprinting effect, and maternal effect. Within each row, there are eight clusters of four bars representing the 8 disease models. The four bars in each cluster represent type I error (denoted as "E") or power (denoted as "P") of $LIME_{DSP}$ and $MCEM_{DSP}$ methods on "SD" data, and $LIME_{DSP}$ and $MCEM_{DSP}$ methods on

"SD+1" data, respectively. According to the disease models, type I error for association effect can be obtained from disease model 1; type I error for imprinting effect can be obtained from disease model 1-4; type I error for maternal effect can be obtained from disease models 1,2, 3, 4, and 6. Powers can be obtained in other disease models.



HWE= 0 maf= 0.1 prev= 0.05

Figure 1.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.1 and prev = 0.05 with 100 families

The figures show that $MCEM_{DSP}$ method can control all the type I error at around 0.05 nominal values, even when HWE does not hold. This means $MCEM_{DSP}$ is very robust to violation of HWE assumption. We can also see that no matter whether the discordant sibpair families have additional siblings or not, $MCEM_{DSP}$ method is generally more powerful than $LIME_{DSP}$. As expected, the powers of the methods with additional siblings are higher than the methods without additional siblings. We can also see that for some settings and scenarios, such as setting 5 and 7 when disease prevalence is 0.05, the imprinting effect power of $MCEM_{DSP}$ for



Figure 2.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.3 and prev = 0.05 with 100 families

the data without additional siblings can be even higher than that of $LIME_{DSP}$ for the data with one additional sibling. The figures show that the power to detect maternal effects are generally very low for both $MCEM_{DSP}$ and $LIME_{DSP}$ methods, especially for the data without additional siblings. The main reason is in discordant sibpair design the affected proband and unaffected proband share the same mother leading to little contrast to detect maternal effect.

Each figure from Figures 3.3 and 3.4 represent first two scenarios when sample size is 500 (Appendix figures 7 - 12 are for the other scenarios). We can see that the powers are generally higher compared to that when sample size is 100, but the results of power comparison between different methods and data types are similar. The type I error, however, show different patterns. Type I errors are generally close to nominal value 0.05, except for imprinting effect when minor allele frequency is



Figure 3.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.1 and prev = 0.05 with 500 families

low and there are no additional siblings, which implies that under this situation, $MCEM_{DSP}$ algorithm cannot converge to the true parameter values, as small minor allele frequency might lead to flat complete log likelihood function. This inflation of type I error might be also related to the confounding between imprinting effect and maternal effect. As we mentioned, maternal effect can mimic paternal imprinting effect. $MCEM_{DSP}$ cannot differentiate the two confounding epigenetic effects in disease model 4 ($(R_1, R_2, R_{im}, S_1, S_2) = (1, 3, 1, 2, 2)$), where there is maternal effect, but no imprinting effect under the scenario MAF=0.1, sample size = 500, and data type="SD".



Figure 4.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.3 and prev = 0.05 with 500 families

5.2. Relative bias of the parameter estimation

We define the relative bias as $\frac{(\hat{\theta}-\theta)}{\theta}$. The relative bias is calculated under each scenario and disease model for discordant sib-pair families with and without additional siblings, and shown in boxplots 3.5 and 3.6 (Appendix figures 13 - 18 are for the other scenarios) when sample size is 100. There are five rows in each of these boxplot figure, representing the relative bias for R_1, R_2, R_{im}, S_1 , and S_2 , respectively. The eight clusters of boxplots represent the eight disease models. The four boxplots in each cluster represent the results for LIMEdsp and MCEMdsp for "SD" data and LIMEdsp and MCEMdsp for "SD+1" data, respectively.

We can see that the relative bias medians for the parameters are all around 0 for both $MCEM_{DSP}$ and $LIME_{DSP}$ under all settings. The interquartile range for R_1 , R_2 , R_{im} , S_2 are generally smaller for $MCEM_{DSP}$. The interquartile range for S_1 is bigger for $MCEM_{DSP}$ when there are no additional sibling, but it becomes smaller than $LIME_{DSP}$ when there are additional siblings.

The Figures 3.7 and 3.8 represent first two scenarios when sample size is 500 (Appendix figures 19 - 24 are for the other scenarios). The relative bias comparison results between the two methods are similar for the two samples sizes, but the interquartile ranges are all smaller when sample size is larger. We can also see that both $MCEM_{DSP}$ and $LIME_{DSP}$ have smaller proportion of wild estimation for the data with larger sizes or with additional siblings.



Figure 5.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.1 and PREV = 0.05 with 100 families



Figure 6.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.3 and PREV = 0.05 with 100 families



Figure 7.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.1 and PREV = 0.05 with 500 families



Figure 8.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.3 and PREV = 0.05 with 500 families



Figure 9.: Comparison of power and type I error of $LIME_{DSP}$, $MCEM_{DSP}$ and importance sampling methods

5.3. Importance Sampling method

Though $MCEM_{DSP}$ estimation gives a tractable solution to the problem arising when E-step is not available in closed form, the computation time cost is a major issue when implementing the $MCEM_{DSP}$ routine.

Let's consider the first disease model in Table 3.1 as an example.

We apply importance sampling based $MCEM_{DSP}$ method for eight disease models

Table 3.: Computational time comparison for $LIME_{DSP}$, $MCEM_{DSP}$ and importance sampling based $MCEM_{DSP}$ methods

Method	Resource	Nodes	Replicates	Computational time
$LIME_{dsp}$	HPCC	nodes = 1	500	10 minutes
$MCEM_{dsp}$	CentOS 7.4	cores = 500	500	10 hours
Importance Sampling			500	4 hour

when Hardy-Weinberg equilibrium (HWE) is 0, disease prevalence (prev) is 0.05 and minor allele frequency (MAF) is set to be 0.1 with sample size 500 for the families with one additional sibling. The simulation shows that, the type I error and the power of importance sampling based $MCEM_{DSP}$ are comparable to $MCEM_{DSP}$ method. For some disease models, the power of the importance sampling based $MCEM_{DSP}$ is a little lower than $MCEM_{DSP}$, but it is still generally higher than $LIME_{DSP}$ method. What's more, the important sampling based $MCEM_{DSP}$ is much more time efficient than $MCEM_{DSP}$ method.

6. Real Data Analysis

To illustrate application of $MCEM_{DSP}$ method we apply it to Framingham Heart Study (FHS). FHS is a long-term, ongoing cardiovascular risk study to examine the epidemiology of cardiovascular diseases on cohorts of residents of Framingham, Massachusetts. This study is considered as the first prospective study on cardiovascular disease which identified risk factors and their joint effects. In FHS several cardiovascular disease conditions were considered including coronary heart disease, stroke, hypertension, peripheral arterial disease, and congestive heart failure. In this study, we focus on hypertension, a multifactorial complex trait, which can increase the risk of coronary heart disease. A person is categorized as hypertensive, if her/his systolic blood pressure is ≥ 140 mmHg or diastolic blood pressure is ≥ 90 mmHg or he/she has taken medication to control blood pressure. In this study, we considered 48071 SNPs in 22 autosomal chromosomes for 263 discordant sib-pair families with 229 additional siblings. As in our simulations, $MCEM_{DSP}$ can control type I error well for all the settings when there are additional siblings, we believe $MCEM_{DSP}$ is also valid in this real data analysis.

Many of the top SNPs identified to be associated with the hypertensive trait by $MCEM_{DSP}$ (Table 3.4) have been previously showed in the literature related to hypertension, cardiovascular disorder or other complex disease. Specifically, SNP rs12117125, inhabiting in the gene FCGR2A on chromosome 1, is found to be associated with Kawasaki disease. It has been identified in association with damage to the coronary arteries, making it a notable contributor to pediatric acquired heart disease. The potential impact on the coronary arteries underscores the significance of addressing and managing this condition in children.[41]. SNP rs12416299 is another SNP identified to be associated with blood pressure, presence of hypertension, and age at onset of hypertension [42]. It is located in the gene SORBS1 on chromosome 10. The gene SVEP1 in chromosome 9 (containing rs1327533) is associated with hypertension and type 2 diabetes [43].

It is worth to discussing several genes found to have an imprinting effect on hypertension (Table 3.4). Previous research suggests that, the gene CD44 in chromosome 11 (containing rs353637) is related to pulmonary arterial hypertension [44]. SNP rs16832560 in gene SOX2-OT in chromosome 3, is also diagnosed as related to pulmonary arterial hypertension which regulates the proliferation, migration, anti-apoptosis, and inflammation of pulmonary artery smooth muscle cells [45]. The gene TRPM8 in chromosome 2 (containing rs7593557) is found to be associated with renin - antiotensin - aldosterone system - mediated hypertension, which subsequently induces small molecule and fluid extravasation, increases plasma Ig levels, and elicits immuno-suppression [46]. Also, according to literature, the gene ATP11A in chromosome 13 (containing rs381583) may act as a susceptibility gene for pulmonary fibrosis and an indicator of pulmonary hypertension [47].

When considering the maternal effect, there are several genes that harbor SNPs which are found to have a significant effect on the hypertensive trait by $MCEM_{DSP}$ (Table 3.4). The previous literature shows that, SNP rs4961, inhabiting in gene ADD1 in chromosome 4, is associated with hypertension. It was found to be significantly associated with increased prevalence of peripheral arterial disease and incidence of coronary heart disease among hypertensive individuals [48]. As another example, rs3811515 within gene SPHKAP (chromosome 2) is associated with hypertension [49]. The gene ROBO4 in chromosome 11 (containing rs7129737) is identified that it has an association with pulmonary artery hypertension [50]. Gene DOT1L in chromosome 19 (containing rs12986413) was found to have a strong association with greater systolic and diastolic blood pressure [51]. However, when considering the top genes, almost all of them have higher minor allele frequency (≥ 0.2). A full list of the top SNPs identified by $MCEM_{DSP}$ can be found in Appendix Table 1,2, and 3.

We also apply $LIME_{DSP}$ method to the FHS data, and calculate the Bonferroni method adjusted p-values. We find that at 0.05 significance level, no SNPs have association, imprinting, or maternal effects based on $LIME_{DSP}$ method. $MCEM_{DSP}$, on the other hand, can identify 45 SNPs with association, 4 SNPs with imprinting effect, and 4 SNPs with maternal effect at 0.05 significance level. This result is consistent with our conclusion in simulations that $MCEM_{DSP}$ is generally more powerful than $LIME_{DSP}$.

Effect	SNP	Chr	Position(BP)	Gene	$-log_{10}$ (P-value)
Association	rs12117125	1	161522658	FCGR2A	12.3787
	rs12416299	10	95542074	SORBS1	15.4775
	rs1327533	9	110368883	SVEP1	12.0632
Imprinting	rs353637	11	35163005	CD44	3.6998
	rs16832560	3	181564785	SOX2-OT	3.6316
	rs7593557	2	233955144	TRPM8	3.5197
Maternal	rs4961	4	2904980	ADD1	4.4915
	rs3811515	2	228018313	SPHKAP	4.2972
	rs7129737	11	124888741	ROBO4	4.1144
	rs12986413	19	2170955	DOT1L	4.0802

Table 4.: Some significant findings of association, imprinting and maternal effects for the Framingham Heart Study data using $MCEM_{DSP}$

7. Concluding Remarks and Summary

Both imprinting and maternal effects are important sources of missing heritability in complex human diseases that cannot be explained by genome-wide association studies. Among all the existing methods to detect these two confounded epigenetic effects, almost all the full likelihood -based methods rely on strong yet unrealistic assumptions concerning mating type probabilities to avoid over parameterization. Two partial likelihood – based methods, LIME and $LIME_{DSP}$, can exceptionally overcome the over-parameterization problem without making those assumptions. LIME requires case families and control families, while $LIME_{DSP}$ only requires families with discordant sibpair that is easier to recruit. Empirical and theoretical results have shown their validity and robustness, but it is likely that these partial likelihood – based methods are less efficient than full-likelihood based methods in term of parameter estimation. An MCEM algorithm was developed to find full likelihood maximizer based on case families and control families and was found to be more powerful than LIME. In this study, we further propose an $MCEM_{DSP}$ algorithm to find full likelihood maximizer based on discordant sibpair design. This $MCEM_{DSP}$ algorithm can detect the two epigenetic effects jointly and can accommodate discordant sibpair families with an arbitrary number of additional siblings.

Expectation maximization method is often used for finding full likelihood maximizer

when there are missing data or unobservable latent random variables. In our study, we use mating type probabilities (the nuisance parameters) as latent random variables in the EM algorithm to get full likelihood maximizer without making assumptions about them. As the expectation in E-step is not in closed format, monte carlo simulations are used to estimate the expectation. Log likelihood ratio test is used to test association, imprinting effect and maternal effect related to the disease of interest. Extensive simulations under different disease models and scenarios demonstrate that the $MCEM_{DSP}$ method can generally control type I error under most scenarios and is more powerful than $LIME_{DSP}$. For some simulation settings, the power gain by using $MCEM_{DSP}$ method instead of $LIME_{DSP}$ method can be even higher than the power gain by recruiting one more additional sibling in each family based on $LIME_{DSP}$. In addition, the parameter estimation based on $MCEM_{DSP}$ method has similar relative bias and generally smaller standard error compared to $LIME_{DSP}$ method. To illustrate the utility of $MCEM_{DSP}$ method, we apply it to Framingham Heart Study data. The results show that many of our findings are consistent with those in the literature, but potential novel genes also emerged.

Despite its advantages, $MCEM_{DSP}$ has several limitations. Firstly, simulations show that the empirical type I error for imprinting effect is inflated when the data include 500 discordant sibpairs without any additional siblings and minor allele frequency is low (0.01). This is probably because the low minor allele frequency leads to a flatter expectation function in the E-step of the algorithm, such that the M-step cannot identify the global likelihood maximizer. Secondly, $MCEM_{DSP}$ algorithm takes much longer time than $LIME_{DSP}$, due to the time cost in generating monte carlo samples in each iteration. To alleviate this problem, we propose an importance sampling based $MCEM_{DSP}$ algorithm, which can reweight and repeatedly use the monte carlo samples in E-step to greatly reduce the time consumption. Besides, simulations show that importance sampling based $MCEM_{DSP}$ algorithm has similar performance as the original $MCEM_{DSP}$.

In future works, we want to explore whether any modification of current $MCEM_{DSP}$ algorithm can correct the type I error inflation under some situations as in the simulations. In addition, we also want to check the possibility of applying $MCEM_{DSP}$ to the data of discordant sibpair families with father's genotype missing. It is well known that fathers are usually much harder to recruit than mothers for a genetic study, and thus a study design with discordant sibpair and their mother may be easier to meeting its target sample size. Nevertheless, with father's genotype missing, when both mother's and child's are heterogeneous, we cannot determine the parental origin of child's minor allele, thus the related penetrance probability calculation will become more complex. $LIME_{DSP}$ actually fails to deal with this type of data, as the related partial likelihood will become no longer free of the nuisance parameters to get rid of the over-parameterization problem. As $MCEM_{DSP}$ algorithm is based on full likelihood, we expect that it can accommodate this type of incomplete family data.

References

- Teri A Manolio, Francis S Collins, Nancy J Cox, David B Goldstein, Lucia A Hindorff, David J Hunter, Mark I McCarthy, Erin M Ramos, Lon R Cardon, Aravinda Chakravarti, et al. Finding the missing heritability of complex diseases. *Nature*, 461(7265):747–753, 2009.
- [2] Jian Yang, Jian Zeng, Michael E Goddard, Naomi R Wray, and Peter M Visscher. Concepts, estimation and interpretation of snp-based heritability. *Nature genetics*, 49(9): 1304–1310, 2017.
- [3] Michael H Guo, Joel N Hirschhorn, and Andrew Dauber. Insights and implications of genome-wide association studies of height. The Journal of Clinical Endocrinology & Metabolism, 103(9):3155–3168, 2018.
- [4] Jo Peters. The role of genomic imprinting in biology and disease: an expanding view. Nature Reviews Genetics, 15(8):517-530, 2014.
- [5] Cathérine Dupont, D Randall Armant, and Carol A Brenner. Epigenetics: definition, mechanisms and clinical perspective. In *Seminars in reproductive medicine*, volume 27, pages 351–357. (C) Thieme Medical Publishers, 2009.
- [6] Takashi Kohda. Effects of embryonic manipulation and epigenetics. Journal of human genetics, 58(7):416-420, 2013.
- [7] Lawrence S Wilkinson, William Davies, and Anthony R Isles. Genomic imprinting effects on brain development and function. *Nature Reviews Neuroscience*, 8(11):832–843, 2007.
- [8] Anne C Ferguson-Smith. Genomic imprinting: the emergence of an epigenetic paradigm. *Nature Reviews Genetics*, 12(8):565–575, 2011.
- [9] Randy L Jirtle and Jennifer R Weidman. Imprinted and more equal. Am Sci, 95:143–149, 2007.
- [10] I Lobo. Genomic imprinting and patterns of disease inheritance. Nat. Educ, 1(5), 2008.
- [11] C David Allis and Thomas Jenuwein. The molecular hallmarks of epigenetic control. *Nature Reviews Genetics*, 17(8):487–500, 2016.
- [12] Raphael Scharfmann and Julian PH Shield. Development of the pancreas and neonatal diabetes, volume 12. Karger Medical and Scientific Publishers, 2007.
- [13] J F Griffiths Anthony. An introduction to genetic analysis. WH Freeman, 1993.
- [14] David Haig. Evolutionary conflicts in pregnancy and calcium metabolism—a review. *Placenta*, 25:S10–S15, 2004.
- [15] Christina GS Palmer, Erin Mallery, Joni A Turunen, Hsin-Ju Hsieh, Leena Peltonen, Jouko Lonnqvist, J Arthur Woodward, and Janet S Sinsheimer. Effect of rhesus d incompatibility on schizophrenia depends on offspring sex. *Schizophrenia research*, 104(1-3): 135–145, 2008.
- [16] Anna C Svensson, Sven Sandin, Sven Cnattingius, Marie Reilly, Yudi Pawitan, Christina M Hultman, and Paul Lichtenstein. Maternal effects for preterm birth: a genetic epidemiologic study of 630,000 families. *American journal of epidemiology*, 170(11): 1365–1372, 2009.
- [17] Heather A Lawson, James M Cheverud, and Jason B Wolf. Genomic imprinting and parent-of-origin effects on complex traits. *Nature Reviews Genetics*, 14(9):609–617, 2013.
- [18] Marisa S Bartolomei. Genomic imprinting: employing and avoiding epigenetic processes. Genes & development, 23(18):2124–2133, 2009.
- [19] MM Patten, L Ross, JP Curley, David C Queller, R Bonduriansky, and JB Wolf. The evolution of genomic imprinting: theories, predictions and empirical tests. *Heredity*, 113 (2):119–128, 2014.
- [20] Ji-Yuan Zhou, Yue-Qing Hu, Shili Lin, and Wing K Fung. Detection of parent-of-origin effects based on complete and incomplete nuclear families with multiple affected children. *Human heredity*, 67(1):1–12, 2009.
- [21] Ji-Yuan Zhou, Jie Ding, Wing K Fung, and Shili Lin. Detection of parent-of-origin effects using general pedigree data. *Genetic epidemiology*, 34(2):151–158, 2010.
- [22] Ji-Yuan Zhou, Wei-Gao Mao, Dan-Ling Li, Yue-Qing Hu, Fan Xia, and Wing Kam Fung.

A powerful parent-of-origin effects test for qualitative traits incorporating control children in nuclear families. *Journal of human genetics*, 57(8):500–507, 2012.

- [23] Jason B Wolf and Michael J Wade. What are maternal effects (and what are they not)? Philosophical Transactions of the Royal Society B: Biological Sciences, 364(1520):1107– 1115, 2009.
- [24] Shili Lin. Assessing the effects of imprinting and maternal genotypes on complex genetic traits. Risk Assessment and Evaluation of Predictions, pages 285–300, 2013.
- [25] Shili Lin. Assessing the effects of imprinting and maternal genotypes on complex genetic traits. Risk Assessment and Evaluation of Predictions, pages 285–300, 2013.
- [26] Jingyuan Yang and Shili Lin. Robust partial likelihood approach for detecting imprinting and maternal effects using case-control families. *The Annals of Applied Statistics*, pages 249–268, 2013.
- [27] CR Weinberg, AJ Wilcox, and RT Lie. A log-linear approach to case-parent-triad data: assessing effects of disease genes that act either directly or through maternal effects and that may be subject to parental imprinting. *The American Journal of Human Genetics*, 62(4):969–978, 1998.
- [28] Miao Han, Yue-Qing Hu, and Shili Lin. Joint detection of association, imprinting and maternal effects using all children and their parents. *European Journal of Human Genetics*, 21(12):1449–1456, 2013.
- [29] Fangyuan Zhang, Abbas Khalili, and Shili Lin. Imprinting and maternal effect detection using partial likelihood based on discordant sibpair data. *Statistica Sinica*, 29(4):1915– 1937, 2019.
- [30] Pooya Aavani. Detecting Imprinting and Maternal Effects Using Monte Carlo Expectation Maximization Algorithm. PhD thesis, 2019.
- [31] Nathalie Peyrard. Convergence of MCEM and related algorithms for hidden Markov random field. PhD thesis, INRIA, 2001.
- [32] Richard A Levine and George Casella. Implementations of the monte carlo em algorithm. Journal of Computational and Graphical Statistics, 10(3):422–439, 2001.
- [33] Greg CG Wei and Martin A Tanner. A monte carlo implementation of the em algorithm and the poor man's data augmentation algorithms. *Journal of the American statistical Association*, 85(411):699–704, 1990.
- [34] Russell A Boyles. On the convergence of the em algorithm. Journal of the Royal Statistical Society: Series B (Methodological), 45(1):47–50, 1983.
- [35] Lei Xu and Michael I Jordan. On convergence properties of the em algorithm for gaussian mixtures. Neural computation, 8(1):129–151, 1996.
- [36] GD Murray. Discussion of the paper by professor dempster et al. Journal of the Royal Statistical Society Series B, 39:27–28, 1977.
- [37] Kenneth Lange. A gradient algorithm locally equivalent to the em algorithm. Journal of the Royal Statistical Society: Series B (Methodological), 57(2):425–437, 1995.
- [38] Ronald C. Neath. On convergence properties of the monte carlo em algorithm. Advances in Modern Statistical Theory and Applications: A Festschrift in honor of Morris L. Eaton, 10:43 - 62, 2013. URL http://dx.doi.org/10.1214/12-IMSCOLL1003.
- [39] KS Chan and Johannes Ledolter. Monte carlo em estimation for time series models involving counts. *Journal of the American Statistical Association*, 90(429):242–252, 1995.
- [40] Stephen P Brooks and Andrew Gelman. General methods for monitoring convergence of iterative simulations. Journal of computational and graphical statistics, 7(4):434–455, 1998.
- [41] Chiea Chuen Khor, Sonia Davila, Willemijn B Breunis, Yi-Ching Lee, Chisato Shimizu, Victoria J Wright, Rae SM Yeung, Dennis EK Tan, Kar Seng Sim, Jie Jin Wang, et al. Genome-wide association study identifies fcgr2a as a susceptibility locus for kawasaki disease. *Nature genetics*, 43(12):1241–1246, 2011.
- [42] Tien-Jyun Chang, Wen-Chang Wang, Chao A Hsiung, Chih-Tsueng He, Ming-Wei Lin, Wayne Huey-Herng Sheu, Yi-Cheng Chang, Tom Quertermous, Ida Chen, Jerome Rotter, et al. Genetic variation in the human sorbs1 gene is associated with blood pressure

regulation and age at onset of hypertension: A sapphire cohort study. *Medicine*, 95(10), 2016.

- [43] In-Hyuk Jung, Jared S Elenbaas, Arturo Alisio, Katherine Santana, Erica P Young, Chul Joo Kang, Puja Kachroo, Kory J Lavine, Babak Razani, Robert P Mecham, et al. Svep1 is a human coronary artery disease locus that promotes atherosclerosis. *Science translational medicine*, 13(586):eabe0357, 2021.
- [44] Sarasa Isobe, Masaharu Kataoka, Jin Endo, Hidenori Moriyama, Shogo Okazaki, Kenji Tsuchihashi, Yoshinori Katsumata, Tsunehisa Yamamoto, Kohsuke Shirakawa, Naohiro Yoshida, et al. Endothelial-mesenchymal transition drives expression of cd44 variant and xct in pulmonary hypertension. *American journal of respiratory cell and molecular biology*, 61(3):367–379, 2019.
- [45] Yunfei Jiang, Bingchang Hei, Wenbo Hao, Shudong Lin, Yuanyuan Wang, Xuzhi Liu, Xianguo Meng, and Zhanjiang Guan. Clinical value of lncrna sox2-ot in pulmonary arterial hypertension and its role in pulmonary artery smooth muscle cell proliferation, migration, apoptosis, and inflammatory. *Heart & Lung*, 55:16–23, 2022.
- [46] Hao Chan, Hsuan-Shun Huang, Der-Shan Sun, Chung-Jen Lee, Te-Sheng Lien, and Hsin-Hou Chang. Trpm8 and raas-mediated hypertension is critical for cold-induced immunosuppression in mice. Oncotarget, 9(16):12781, 2018.
- [47] Haomin Cai and Hongcheng Liu. Immune infiltration landscape and immune-marker molecular typing of pulmonary fibrosis with pulmonary hypertension. BMC Pulmonary Medicine, 21(1):1–15, 2021.
- [48] Alanna C Morrison, Molly S Bray, Aaron R Folsom, and Eric Boerwinkle. Add1 460w allele associated with cardiovascular disease in hypertensive individuals. *Hypertension*, 39(6):1053–1057, 2002.
- [49] Mogens Fenger, Allan Linneberg, Torben Jørgensen, Sten Madsbad, Karen Søbye, Jesper Eugen-Olsen, and Jørgen Jeppesen. Genetics of the ceramide/sphingosine-1-phosphate rheostat in blood pressure regulation and hypertension. BMC genetics, 12(1):1–18, 2011.
- [50] C Hadinnapola, M Southwood, D Jenkins, K Sheares, M Toshner, and J Pepke-Zaba Papworth. P16 a systematic characterisation of inflammation in chronic thromboembolic pulmonary hypertension. *Thorax*, 69(2):A1–A233, 2014.
- [51] Julio D Duarte, Issam Zineh, Ben Burkley, Yan Gong, Taimour Y Langaee, Stephen T Turner, Arlene B Chapman, Eric Boerwinkle, John G Gums, Rhonda M Cooper-DeHoff, et al. Effects of genetic variation in h3k79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. *Journal of translational medicine*, 10(1):1–9, 2012.

Appendix A. Conditional distribution of subvector of a Dirichlet random variable

Let, $Z = (Z_1, ..., Z_k)$ follows a Dirichlet distribution with parameters $(\alpha_1, ..., \alpha_k)$. Then, let $(1, ..., k) = (A_1, A_2)$ and $Z = (Z_{A_1}, Z_{A_2})$ By the definition of joint pdf of $(Z_1, ..., Z_k)$;

$$f_{Z_1,\dots,Z_k}(z_1,\dots,z_k) = \frac{\Gamma(\sum_{i=1}^k \alpha_i)}{\prod_{i=1}^k \Gamma(\alpha_i)} \prod_{i=1}^k z_i^{\alpha_i - 1}, z_i \in (0,1), \sum_{i=1}^k z_i = 1$$
(A1)

Similarly, the joint pdf of Z_{A_2} is;

$$f_{Z_{A_2}}(z_{A_2}) = \frac{\Gamma(\sum_{i=1}^k \alpha_i)}{\Gamma(\alpha_0) \prod_{i \in A_2} \Gamma(\alpha_i)} \prod_{i \in A_2} z_i^{\alpha_i - 1} \left(1 - \sum_{i \in A_2} z_i\right)^{\alpha_0 - 1}$$
(A2)

where, $\alpha_0 = \sum_{i \in A_1} \alpha_i$. Then, the conditional pdf of $Z_{A_1} | Z_{A_2}$ is given by;

$$f_{Z_{A_1}|Z_{A_2}}(z_{A_1}|z_{A_2}) = \frac{\Gamma(\sum_{i \in A_1} \alpha_i)}{\prod_{i \in A_1} \Gamma(\alpha_i)} \prod_{i \in A_1} z_i^{\alpha_i - 1} \left(1 - \sum_{i \in A_2} z_i\right)^{-(\alpha_0 - 1)} = \frac{\Gamma(\sum_{i \in A_1} \alpha_i)}{\prod_{i \in A_1} \Gamma(\alpha_i)} \prod_{i \in A_1} \left[z_i \left(1 - \sum_{i \in A_2} z_i\right)^{-1}\right]^{\alpha_i - 1} \left(1 - \sum_{i \in A_2} z_i\right)^{-(m-1)}$$
(A3)

When $m = \text{length}(A_1)$, $Z_{A_1}|Z_{A_2} = z_{A_2}$ has a scaled Dirichlet distribution;

$$\frac{1}{1 - \mathbf{1}^T z_{A_2}} Z_{A_1} | Z_{A_2} = z_{A_2} \sim Dir(\alpha_{A_1})$$
(A4)

where **1** is the vector with length k - m and all entries equal to 1.

Appendix B. Calculation of Probabilities in Table 3.2

In Table 3.2, the formula to calculate the joint probability is as follows:

$$\begin{split} P(M = m, F = f, C_1 = c_1, C_2 = c_2, D_1 = 1, D_2 = 0) \\ = P(M = m, F = f).P(C_1 = c_1 | M = m, F = f).P(C_2 = c_2 | M = m, F = f) \\ \times P(D_1 = 1 | M = m, F = f, C_1 = c_1).P(D_2 = 0 | M = m, F = f, C_2 = c_2). \end{split}$$

For all types other than types 12, 13, 14, 18 and 19 (Table 3.2), if a child has one copy of the variant allele, the parental origin can be unambiguously identified, and hence the joint probability can be easily obtained by extracting the relevant factors from the relative risk models for disease prevalence: $P(D_1 = 1|M = m, F = f, C_1 = c_1) = \delta R_1^{I(c_1=1)} R_2^{I(c_1=2)} R_{im}^{I(c_1=1_m)} S_1^{I(M=1)} S_2^{I(M=2)},$ $P(D_2 = 0|M = m, F = f, C_2 = c_2) = 1 - \delta R_1^{I(c_2=1)} R_2^{I(c_2=2)} R_{im}^{I(c_2=1_m)} S_1^{I(M=1)} S_2^{I(M=2)},$ For example, in the familial genotype combination $(m, f, c_1, c_2) = (2, 0, 1, 1),$

$$\begin{split} P(M=2,F=0,C_1=1,C_2=1,D_1=1,D_2=0) &= P(M=2,F=0)\\ .P(C_1=1|M=2,F=0).P(C_2=1|M=2,F=0)\\ .P(D_1=1|M=2,F=0,C_1=1)\\ .P(D_2=0|M=2,F=0,C_2=1)\\ &= \mu_{20}\delta r_1 s_2 r_{im}(1-\delta r_1 s_2 r_{im}). \end{split}$$

For type 12, in which $(m, f, c_1, c_2) = (1, 1, 1, 0)$, as the variant allele carried by the affected child can be inherited either from the mother or the father with equal probabilities, the penetrance probability ends up being a equally weighted summation. That is,

$$P(D_1 = 1 | M = 2, F = 0, C_1 = 1) = \frac{1}{2} [\delta r_1 s_1 + \delta r_1 r_{im} s_1]$$
$$= \frac{1}{2} \delta r_1 s_1 (1 + r_{im}).$$

Then the joint probability can be written as,

$$\begin{split} P(M=1,F=1,C_1=1,C_2=0,D_1=1,D_2=0) &= P(M=1,F=1)\\ .P(C_1=1|M=1,F=1).P(C_2=0|M=1,F=1)\\ .P(D_1=1|M=1,F=1,C_1=1)\\ .P(D_2=1|M=1,F=1,C_2=0)\\ &= \mu_{11}.\frac{1}{2}.\frac{1}{4}.\frac{1}{2}\delta r_1s_1(1+r_{im}).(1-\delta s_1)\\ &= \mu_{11}\frac{1}{16}\delta r_1s_1(1+r_{im})(1-\delta s_1). \end{split}$$

For type 13, in which $(m, f, c_1, c_2) = (1, 1, 0, 1)$, the variant allele carried by the unaffected child can be inherited either from the mother or the father with equal probabilities and, as such, the penetrance probability ends up being the summation of two penetrance probabilities weighted equally. That is,

$$P(D_2 = 0 | M = 1, F = 1, C_2 = 1) = \frac{1}{2} [(1 - \delta r_1 s_1) + (1 - \delta r_1 s_1 r_{im})]$$
$$= \frac{1}{2} [2 - \delta r_1 s_1 (1 + r_{im})].$$

Then, the joint probability can be written as,

$$\begin{split} P(M=1,F=1,C_1=0,C_2=1,D_1=1,D_2=0) &= P(M=1,F=1)\\ .P(C_1=0|M=1,F=1).P(C_2=1|M=1,F=1)\\ .P(D_1=1|M=1,F=1,C_1=0)\\ .P(D_2=0|M=1,F=1,C_2=1)\\ &= \mu_{11}.\frac{1}{4}.\frac{1}{2}.\frac{1}{2}\delta s_1.\frac{1}{2}[2-\delta r_1s_1(1+r_{im})]\\ &= \mu_{11}\frac{1}{16}\delta s_1[2-\delta r_1s_1(1+r_{im})]. \end{split}$$

For type 14, in which $(m, f, c_1, c_2) = (1, 1, 1, 1)$, the variant allele carried by the both affected and unaffected child can be inherited either from the mother or the father with equal probabilities and, as such, the penetrance probability ends up being a equally weighted summation.

$$\begin{split} P(M=1,F=1,C_1=1,C_2=1,D_1=1,D_2=0) &= P(M=1,F=1)\\ .P(C_1=1|M=1,F=1).P(C_2=1|M=1,F=1)\\ .P(D_1=1|M=1,F=1,C_1=1)\\ .P(D_2=1|M=1,F=1,C_2=1)\\ &= \mu_{11}.\frac{1}{2}.\frac{1}{2}.\frac{1}{2}\delta r_1s_1(1+r_{im}).\frac{1}{2}[2-\delta r_1s_1(1+r_{im})]\\ &= \mu_{11}\frac{1}{16}\delta r_1s_1(1+r_{im})[2-\delta r_1s_1(1+r_{im})]. \end{split}$$

We can follow similar procedures to derive the joint probabilities for other settings.

HWE= 0 maf= 0.1 prev= 0.15 1.00-0.75 -0.50 -0.25 -0.00-5 ż 6 7 8 2 4 1.00-Model 0.75 -1,50 -1,25 -LIMEdsp MCEMdsp LIMEdsp_sibl E E E E MCEMdsp sibl 0.00ż 5 6 8 1 2 3 4 1.00under 0.50 -Mate 0.25 -E Ε 0.00-2 3 7 8 5 6 1

Figure C1.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.1 and prev = 0.15 with 100 families

Appendix D. Real data Analysis



HWE= 0 maf= 0.3 prev= 0.15

Figure C2.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.3 and prev = 0.15 with 100 families



HWE= 1 maf= 0.1 prev= 0.05

Figure C3.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.1 and prev = 0.05 with 100 families



HWE= 1 maf= 0.3 prev= 0.05

Figure C4.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.3 and prev = 0.05 with 100 families



Figure C5.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.1 and prev = 0.15 with 100 families



HWE= 1 maf= 0.3 prev= 0.15

Figure C6.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.3 and prev = 0.15 with 100 families



Figure C7.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.1 and prev = 0.15 with 500 families



Figure C8.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 0, maf = 0.3 and prev = 0.15 with 500 families



Figure C9.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.1 and prev = 0.05 with 500 families



HWE= 1 maf= 0.3 prev= 0.05

Figure C10.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.3 and prev = 0.05 with 500 families



Figure C11.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.1 and prev = 0.15 with 500 families



Figure C12.: Bar charts for compare type I error and power of $MCEM_{DSP}$ and $LIME_{DSP}$ methods with and without additional siblings when HWE = 1, maf = 0.3 and prev = 0.15 with 500 families



Figure C13.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.1 and PREV = 0.15 with 100 families



Figure C14.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.3 and PREV = 0.15 with 100 families



Figure C15.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.1 and PREV = 0.05 with 100 families



Figure C16.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.3 and PREV = 0.05 with 100 families



Figure C17.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.1 and PREV = 0.15 with 100 families



Figure C18.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.3 and PREV = 0.15 with 100 families



Figure C19.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.1 and PREV = 0.15 with 500 families



Figure C20.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 0, maf = 0.3 and PREV = 0.15 with 500 families



Figure C21.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.1 and PREV = 0.05 with 500 families



Figure C22.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.3 and PREV = 0.05 with 500 families



Figure C23.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.1 and PREV = 0.15 with 500 families



Figure C24.: Box plots for biases of parameters from $MCEM_{DSP}$ and $LIME_{DSP}$ methods when HWE = 1, maf = 0.3 and PREV = 0.15 with 500 families

Rank	SNP	Chr	Position(BP)	Gene	$-log_{10}$ P-value	
					$MCEM_{DSP}$	$LIME_{DSP}$
1	rs5760711	22	24894886	SGSM1	15.9546	0.4676
2	rs12416299	10	95542074	SORBS1	15.4775	0.2365
3	rs340719	2	16222132		14.8754	0.4882
4	rs2973566	5	73852656	ARHGEF28	14.8404	0.4387
5	rs11539522	15	49625193	DTWD1	14.6122	0.4878
6	rs1146920	13	77760082	SLAIN1	12.6497	0.4622
7	rs12117125	1	161522658	FCGR2A	12.3787	0.4241
8	rs2666954	6	380789		12.0756	0.4285
9	rs6076157	20	23882207		12.0674	0.4477
10	rs1327533	9	110368883	SVEP1	12.0632	0.2198
11	rs12306837	12	4571302	DYRK4	11.7532	0.4845
12	rs2281954	10	125796084	UROS	11.5686	0.4690
13	rs11033793	11	4769244	MMP26	11.4601	0.1714
14	rs12345874	9	68776727	PIP5K1B	10.5720	0.4487
15	rs3829736	12	47982720	COL2A1	10.2677	0.3841
16	rs9367018	6	12173899	HIVEP1	9.6447	0.4840
17	rs12197569	6	2164221	GMDS	9.3021	0.4700
18	rs7124812	11	3439368	LOC124902616	8.8759	0.3451
19	rs9382736	6	57436863	PRIM2	8.8020	0.4176
20	rs16843643	2	241413353	FARP2	8.6881	0.4622

Table D1.: Top 20 significant SNPs for association with Framingham Heart Study data using $MCEM_{DSP}$

Rank	SNP	Chr	Position(BP)	Gene	$-log_{10}$ F	-value
					$MCEM_{DSP}$	$LIME_{DSP}$
1	rs2281954	10	125796084	UROS	12.7598	0.4690
2	rs7124812	11	3439368	LOC124902616	8.3917	0.3451
3	rs7928271	11	126918754	KIRREL3	5.9070	0.4653
4	rs6543298	2	98131244	VWA3B	4.9663	0.4565
5	rs2860161	7	142824583		4.8961	0.2271
6	rs6886844	5	105942041		4.8306	0.3260
7	rs6485742	11	12432529	PARVA	4.7765	0.3281
8	rs2059928	15	22152346		4.7728	0.3815
9	rs3734945	7	138621037	SVOPL	4.7018	0.3498
10	rs1729086	2	231343344	ARMC9	4.0955	0.1001
11	rs2282537	11	120317262	POU2F3	3.9273	0.1291
12	rs1106337	1	167166482	LOC105371601	3.7137	0.0351
13	rs353637	11	35163005	CD44	3.6998	0.1287
14	rs13209741	6	1528900	LOC102723944	3.6427	0.1949
15	rs16832560	3	181564785	SOX2-OT	3.6316	0.1060
16	rs818055	9	131092123	LAMC3	3.6123	0.2010
17	rs10018350	4	6320374	PPP2R2C	3.5524	0.1383
18	rs949292	18	60501574		3.5417	0.3216
19	rs6878253	5	132277600	LOC124901063	3.5211	0.0858
20	rs7593557	2	233955144	TRPM8	3.5197	0476

Table D2.: Top 20 significant SNPs for imprinting with Framingham Heart Study data using $MCEM_{DSP}$

Rank	SNP	Chr	Position(BP)	Gene	$-log_{10}$ F	-value
					$MCEM_{DSP}$	$LIME_{DSP}$
1	rs9294284	6	83954925	CYB5R4	279.1653	0.4817
2	rs4660212	1	42030728	HIVEP3	6.6689	0.4603
3	rs6485742	11	12432529	PARVA	6.4115	0.3281
4	rs7835497	8	39765231	ADAM2	5.61404	0.1476
5	rs8130490	21	18355236	TMPRSS15	5.5795	0.4691
6	rs5022654	9	4766378		4.8936	0.0844
7	rs12306837	12	4571302	DYRK4	4.6017	0.4845
8	rs7928271	11	126918754	KIRREL3	4.5619	0.4643
9	rs3751020	11	119608340		4.5395	0.3099
10	rs4961	4	2904980	ADD1	4.4915	0.1957
11	rs12197569	6	2164221	GMDS	4.3880	0.4700
12	rs12703608	7	144547846	TPK1	4.3071	0.0997
13	rs3811515	2	228018313	SPHKAP	4.2972	0.2384
14	rs4814626	20	17580396	DSTN	4.2546	0.1779
15	rs17594685	13	41679215	VWA8	4.1531	0.1108
16	rs7129737	11	124888741	ROBO4	4.1144	0.1369
17	rs12986413	19	2170955	DOT1L	4.0802	0.4825
18	rs10807372	6	47681838	ADGRF2	4.066	0.3564
19	rs10188832	2	16621901	CYRIA	4.0573	0.2162
20	rs11595441	10	15010629		4.0397	0.4536

Table D3.: Top 20 significant SNPs for maternal with Framingham Heart Study data using $MCEM_{DSP}$